Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,552.12
(
-0.82%
)
US TECH 100
23,440.00
(
-1.18%
)
Dow Jones
45,820.25
(
-0.44%
)
Brent Oil
106.75
(
2.22%
)
Bitcoin
69,748.00
(
-0.22%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 164642

Monday, 07/29/2013 11:44:34 PM

Monday, July 29, 2013 11:44:34 PM

Post# of 257262

VRTX thinks they have enough data to ultimately get the 200mg dose off of hold (assume part of that is the actual data in EU patients at 200mg dose plus other pre-clinical data).

I would take the other side of that bet. The plasma concentration of VX-135 in the dosing range in question is approximately linear, and a 0.5x safety margin (200mg relative to 400mg) is not a lot.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today